Professor, Medicine, Boston University School of Medicine

Pulmonology

Harrison Farber works in the field of Pulmonology. He attended George Washington University School of Medicine. George Washington University School of Medicine is ranked 67 in research and 0 in primary care medicine He received 3 awards: "Boston Magazine", "Elected Member" and "Top MD". Doctor Harrison W. Farber, MD is also a published physician. He has 52 publication published. The most recent publication is: Effect of Warfarin Treatment on Survival of Patients with Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management ... He is registered with Medicare and accepts Medicare payments.

Publications

---

• Clinical features of Pulmonary arterial hypertension in patients receiving dasatinib.
• Novel investigational therapies for treating Pulmonary arterial hypertension.
• Effect of Warfarin Treatment on Survival of Patients with Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management ...
• Perspectives on oral Pulmonary hypertension therapies recently approved by the u.s. Food and drug administration.
• Pharmacokinetic evaluation of treprostinil (oral) for the treatment of Pulmonary arterial hypertension.
• Predicting outcomes in Pulmonary arterial hypertension based on the 6-minute walk distance.
• "Who'll be the next in line?" The lung allocation score in patients with Pulmonary arterial hypertension.
• Cause of death in patients with Pulmonary arterial hypertension.
• Treatment of patients with Pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry.
• Transcatheter Potts shunt creation in patients with severe Pulmonary arterial hypertension: initial clinical experience.
• Increased expression of endoplasmic reticulum stress genes in patients with limited cutaneous systemic sclerosis and Pulmonary arterial hypertension.
• Demographics and outcomes of patients diagnosed with Pulmonary hypertension with Pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry.
• Pulmonary hypertension: screening and evaluation in scleroderma.
• Interferon and alternative activation of macrophage/monocytes in systemic sclerosis-associated Pulmonary arterial hypertension.
• Delay in recognition of Pulmonary arterial hypertension: factors identified from the REVEAL Registry.
• REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with Pulmonary arterial hypertension.
• Differential response to intravenous prostacyclin analog therapy in patients with Pulmonary arterial hypertension.
• The changing picture of patients with Pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.
• Care of patients with scleroderma in the intensive care setting.
• Ethical issues associated with globalization of placebo-controlled in Pulmonary arterial hypertension.
• Early pulmonary embolectomy for Acute pulmonary embolus: an operation whose time has come.
• Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and Pulmonary arterial hyperte...
• The accuracy of the central venous blood gas for acid-base monitoring.
• The role of aldosterone in Pulmonary venous hypertension.
• Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.
• Pulmonary hypertension associated with left ventricular diastolic dysfunction.
• Limited systemic sclerosis patients with Pulmonary arterial hypertension show biomarkers of inflammation and vascular injury.
• Adiponectin deficiency: a model of Pulmonary hypertension associated with Pulmonary vascular disease.
• Dosing considerations in the use of intravenous prostanoids in Pulmonary arterial hypertension: an experience-based review.
• Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: differential expression patterns in Pulmonary artery and microvascular endothelial cells.
• Propylene glycol accumulation during continuous-infusion lorazepam in critically ill patients.
• Design of the REVEAL registry for US patients with Pulmonary arterial hypertension.
• Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression.
• The status of Pulmonary arterial hypertension in 2008.
• Sarcoidosis-associated Pulmonary hypertension: outcome with long-term epoprostenol treatment.
• Conversion to bosentan from prostacyclin infusion therapy in Pulmonary arterial hypertension: a pilot study.
• Imatinib mesylate in the treatment of refractory idiopathic Pulmonary arterial hypertension.
• Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature.
• Synthesis and biological properties of the fluorescent ether lipid precursor 1-O-[9'-(1''-pyrenyl)]nonyl-sn-glycerol.
• Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with Pulmonary arterial hypertension.
• Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study.
• Differential gene expression in Pulmonary artery endothelial cells exposed to sickle cell plasma.
• Sickle cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70.
• Mechanism of disease: Pulmonary hypertension.
• Pulmonary arterial hypertension.
• Mycobacterium marinum osteomyelitis.
• Increasing plasmalogen levels protects human endothelial cells during hypoxia.
• Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis.
• Identification of protein disulfide isomerase as an endothelial hypoxic stress protein.
• Cellular glutathione peroxidase deficiency and endothelial dysfunction.
• Outcome after cardioPulmonary resuscitation in patients with Pulmonary arterial hypertension.

Schools

---

• George Washington University School Of Medicine

• Med College Va

• Boston University School Med

Procedures Preformed

---

• Bronchoscopy
• Thoracentesis
• Ventilation Management

Conditions Treated

---

• Acidosis
• Acute Pharyngitis
• Alkalosis
• Asthma
• View All

Doctors Specialties

---

• Critical Care Medicine
• Pulmonology

Accepted Insurances

---

Awards

---

• Boston Magazine
• Elected Member
• Top MD

Education

---

• Boston University Medical Center
• Virginia Commonwealth University Health System
• George Washington University School of Medicine

Hospital

---

• Boston Medical Center

Drug Facts

---

NPI NUMBER		1396721841
NPPES Provider LastName		FARBER
NPPES Provider FirstName		HARRISON
NPPES Provider ZIPCode		021182526
NPPES Provider State		MA
Specialty Description		Pulmonary Disease
Total Claim Count		954.0
Distinct Opioid Count		1.0
Opioid Claim Count		13.0
Percent Opioid Claims		1.36

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1396721841
Last Name Of The Provider	FARBER
First Name Of The Provider	HARRISON
View All

Similar Doctors

---

	Dr. Paul E. Bettencourt, MD
	Dr. Adel R. El Boueiz, MD This Doctor is OpenDoctor Recommended.
	Dr. Salma Batool-Anwar, MD This Doctor is OpenDoctor Recommended.
	Dr. Scott T. Weiss, MD This Doctor is OpenDoctor Recommended.
	Dr. Sharma E. Joseph, MD This Doctor is OpenDoctor Recommended.
	Dr. Michelle A. Yu, MD
	Dr. Robert W. Hallowell, MD This Doctor is OpenDoctor Recommended.
	Dr. Sean A. Gilman, MD This Doctor is OpenDoctor Recommended.
	Dr. Ednan K. Bajwa, MD This Doctor is OpenDoctor Recommended.
	Dr. Gary R. Epler, MD This Doctor is OpenDoctor Recommended.
	Dr. David J. Kanarek, MD This Doctor is OpenDoctor Recommended.
	Dr. Anne E. O'Donnell, MD This Doctor is OpenDoctor Recommended.
	Dr. Coralynn S. Sack, MD This Doctor is OpenDoctor Recommended.
	Dr. Mark Bradford, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog